Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net earnings	$ 9,458	$ 17,469
Noncash items:
Depreciation and amortization	3,058	2,998
Deferred income taxes	(234)	(494)
Share-based compensation	831	851
Loss on sale of subsidiary and subsidiaries held for sale	8,331	0
Other, net	(610)	(59)
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable	685	(2,574)
Other assets	(2,988)	(2,358)
Medical costs payable	2,235	3,837
Accounts payable and other liabilities	1,250	2,370
Unearned revenues	(181)	12,221
Cash flows from operating activities	21,835	34,261
Investing activities
Purchases of investments	(19,951)	(12,998)
Sales of investments	15,065	3,674
Maturities of investments	6,738	6,474
Cash paid for acquisitions and other transactions, net of cash assumed	(11,674)	(8,389)
Purchases of property, equipment and capitalized software	(2,587)	(2,427)
Loans to care providers - cyberattack	(8,904)	0
Repayments of care provider loans - cyberattack	3,189	0
Other, net	(1,284)	(721)
Cash flows used for investing activities	(19,408)	(14,387)
Financing activities
Common share repurchases	(4,028)	(6,500)
Cash dividends paid	(5,601)	(5,023)
Proceeds from common stock issuances	1,611	1,039
Repayments of long-term debt	(2,500)	(2,125)
(Repayments of) proceeds from short-term borrowings, net	(191)	1,579
Proceeds from issuance of long-term debt	17,811	6,394
Customer funds administered	(1,059)	2,037
Other, net	(1,213)	(1,774)
Cash flows from (used for) financing activities	4,830	(4,373)
Effect of exchange rate changes on cash and cash equivalents	(30)	49
Increase in cash and cash equivalents, including cash within businesses held for sale	7,227	15,550
Less: cash within businesses held for sale	(254)	0
Net increase in cash and cash equivalents	6,973	15,550
Cash and cash equivalents, beginning of period	25,427	23,365
Cash and cash equivalents, end of period	$ 32,400	$ 38,915